BeOne Medicines ONC
Oncology drugs. BeOne Medicines AG, listed on NASDAQ.
Based on the FY2025 annual report (Jan 2025 – Dec 2025)
BeOne Medicines' market cap is
about $44.19 billion.
#241 by market cap among 289 companies, based on the Nov 5, 2026 close. FY2025 revenue was $5.343033B.
- Share price (close)
- $387.25
- P/E ratio
- 2,038.2x
- Market cap
- $44.19B
- Revenue
- $5.343033B
- Operating income
- $447.136M
- Net income
- $286.933M
- Free cash flow
- $941.741M
- Total assets
- $8.188573B
- Dividends paid
- —
- Dividend per share
- —
- Dividend yield
- —
- Shares outstanding
- 1,441,075,618 shares
Where the revenue went
Revenue is set at 100% and split into what went to costs, R&D, operating expenses and taxes, and what was left as profit.
- R&D40.2%
- SG&A and other51.5%
- Taxes, interest & other3.0%
- Net income5.4%
Profitability and stability
Each figure comes with its rank among 300 companies. The further right the dot, the higher the rank.
- Revenue growthHow much revenue grew from the previous fiscal year
- +40.2%
- #14 of 299
- Revenue grew sharply over the year. The median across 299 companies is +7.9%.
- Operating marginShare of revenue kept as profit from the core business
- 8.4%
- #182 of 231
- 8.4% of revenue was kept as operating profit, which is on the low side. The median across 231 companies is 19.2%.
- Net marginShare of revenue left as profit after interest and taxes
- 5.4%
- #244 of 298
- After taxes, 5.4% of revenue was left as net income. The median across 298 companies is 14.0%.
- FCF marginShare of revenue left as cash after capital spending
- 17.6%
- #114 of 261
- Cash is left over after capital spending. The median across 261 companies is 15.8%.
- ROEHow much profit the company earned on shareholders' equity in a year
- 7.5%
- #226 of 276
- Earnings relative to equity are on the low side. The median across 276 companies is 16.8%.
- Debt-to-equityLiabilities relative to equity. Lower means less debt
- 87.8%
- #60 of 244
- Liabilities are smaller than equity. The median across 244 companies is 159.6%.
Revenue and profit over time
Gray bars show revenue and the green part inside shows net income. The number above each bar is revenue (abbreviated) and the number below is net margin. Hover over a bar to see the exact amounts.
Where the cash went
Unlike profit, cash flow is money that actually came in and went out.
- Cash from operations$1.12758B
- Capital spending−$185.839M
- Free cash flow (FCF)$941.741M
Whose money funds the assets
The company's assets, split into borrowed money (liabilities) and shareholders' money (equity).
- Total assets$8.188573B
- Total liabilities$3.827379B
- Total equity$4.361194B
- Cash and equivalents$4.54753B
Compared with similar companies
Based on each company's latest annual report, so fiscal year ends may differ.
Compare in detail| Company | Annual revenue | Net income | Revenue growth | Operating margin | Net margin |
|---|---|---|---|---|---|
| BeOne MedicinesONC | $5.343033B | $286.933M | +40.2% | 8.4% | 5.4% |
| Revolution MedicinesRVMD | $0 | −$1.131301B | — | — | — |
| NateraNTRA | $2.306113B | −$208.16M | +35.9% | −13.4% | −9.0% |
| BiogenBIIB | $9.8906B | $1.2929B | +2.2% | — | 13.1% |
| RegeneronREGN | $14.3429B | $4.5049B | +1.0% | 24.9% | 31.4% |
What the company does
BeOne Medicines is a biotech company that develops and sells cancer drugs, including the blood cancer treatment Brukinsa. It was formerly called BeiGene.
The fiscal year ends around December each year.
Related companies: Revolution Medicines, Natera, Biogen, Regeneron
Financial statements
Last 5 fiscal years. Currency: US dollars.
Show the table
| Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 1.176283B | 1.415921B | 2.458779B | 3.810241B | 5.343033B |
| Gross profit | 1.011377B | 1.129446B | 2.078859B | 3.216152B | 4.674493B |
| R&D expense | 1.459239B | 1.640508B | 1.778594B | 1.953295B | 2.145868B |
| Operating income | −1.438735B | −1.789665B | −1.207736B | −568.199M | 447.136M |
| Pretax income | −1.438588B | −1.961037B | −825.836M | −533.001M | 416.854M |
| Net income | −1.457816B | −2.003815B | −881.708M | −644.786M | 286.933M |
| EPS (diluted) | $-1.21 | $-1.49 | $-0.65 | $-0.47 | $0.19 |
| Operating cash flow | −1.298723B | −1.496619B | −1.157453B | −140.631M | 1.12758B |
| Capital expenditures | 262.942M | 325.434M | 561.896M | 492.663M | 185.839M |
| Free cash flow (FCF) | −1.561665B | −1.822053B | −1.719349B | −633.294M | 941.741M |
| Total assets | 8.535525B | 6.37929B | 5.805275B | 5.92091B | 8.188573B |
| Total liabilities | 2.402962B | 1.995935B | 2.267948B | 2.588688B | 3.827379B |
| Total equity | 6.132563B | 4.383355B | 3.537327B | 3.332222B | 4.361194B |
| Cash and equivalents | 4.375678B | 3.869564B | 3.1718B | 2.62741B | 4.54753B |
| Original filing | 10-K | 10-K | 10-K | 10-K | 10-K |
Source: SEC EDGAR filings for BeOne Medicines AG · CIK 0001651308 · US-GAAP